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In-depth investigations of the safety and immunogenicity of inactivated SARS-CoV-2 vaccines 50 
are needed. 51 
METHOD 52 
In a phase I randomized, double-blinded, and placebo-controlled trial involving 192 healthy 53 
adults 18-59 years of age, two injections of three different doses (50 EU, 100 EU and 150 EU) 54 
of an inactivated SARS-CoV-2 vaccine or the placebo were administered intramuscularly with 55 
a 2- or 4-week interval between the injections. The safety and immunogenicity of the vaccine 56 
were evaluated within 28 days. 57 
FINDING 58 
In this study, 191 subjects assigned to three doses groups or the placebo group completed 59 
the 28-day trial. There were 44 adverse reactions within the 28 days, most commonly mild 60 
pain and redness at the injection site or slight fatigue, and no abnormal variations were 61 
observed in 48 cytokines in the serum samples of immunized subjects. The serum samples 62 
diluted from 1:32 to 1:4096 and incubated with the virus did not show antibody-dependent 63 
enhancement effects (ADEs) with regard to human natural killer cells, macrophages or 64 
dendritic cells. At day 14, the seroconversion rates had reached 92%, 100% and 96% with 65 
geometric mean titers (GMTs) of 18.0, 54.5 and 37.1, and at day 28, the seroconversion rates 66 
had reached 80%, 96% and 92% with GMTs of 10.6, 15.4 and 19.6in 0, 14 and 0, 28 67 
procedures, respectively. Seroconversion was associated with the synchronous upregulation 68 
of ELISA antibodies against the S protein, N protein and virion and a cytotoxic T lymphocyte 69 
(CTL) response. Transcriptome analysis shaped the genetic diversity of immune response 70 
induced by the vaccine. 71 
INTERPRETATION 72 
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In a population aged 18-59 years, this inactivated SARS-CoV-2 vaccine was safe and 73 
immunogenic. 74 
Trial registration: NCT04412538 75 
FUNDING: The National Key R&D Program of China (2020YFC0849700), the Program of 76 
Chinese Academy of Medicine Science and the Major Science and Technology Special 77 
Projects of Yunnan Province. 78 
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Coronavirus disease 2019 (COVID-19) is caused by a novel member of the Coronaviridae 80 
family called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). From the 81 
emergence of COVID-19 at the end of 2019 to September 2020, more than 26 million cases 82 
and more than 800,000 deaths had been recorded, indicating that COVID-19 poses a 83 
substantial threat to public health worldwide 
1
. Because of the highly contagious nature of 84 
SARS-CoV-2 and the severe clinical outcomes 
2,3
, one of the primary strategies to control the 85 
pandemic is to develop an effective vaccine, and within a short period, clinical trials of 86 
several vaccines have been initiated 
4-7
. To date, the data obtained from phase I/II clinical 87 
trials have focused on serological detection to assess the immunogenicity of these vaccines 88 
4,7,8
. The data suggest that SARS-CoV-2, an enveloped virus, possesses various encoded 89 
antigenic components, including S (spike), N (nucleocapsid), E (envelope) and M (membrane) 90 
antigens 
9
, all of which might theoretically be recognized by the immune system during 91 
infection; however, the key antigen is the S protein, which mediates virion entry into cells by 92 
interacting with the ACE2 receptor 
10
. Our previous work, based on an analysis of the 93 
composition of antibodies in convalescent serum from COVID-19 patients, suggested a 94 
technical strategy for the preparation of an inactivated SARS-CoV-2 vaccine in which the 95 
inactivation process yields an inactivated virion exposing the S, N and other viral antigens. 96 
This vaccine was found to effectively elicit immune protection in nonhuman primates under 97 
viral challenge and was approved for a phase I clinical trial (permission number: 2020L00020 98 
by the Chinese Food and Drug Administration (CFDA); clinical trial registration number: 99 
NCT04412538). Here, we further investigated the safety and immunogenicity of this vaccine 100 
in immunized individuals in a phase I trial, especially focusing on safety with regard to the 101 
immunopathology of the vaccine. The results obtained are encouraging, and further study is 102 
needed. 103 
 104 
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Materials and Methods 105 
Viruses and cells 106 
All SARS-CoV-2 virus strains used in this work were isolated from hospitalized patients 107 
including indigenous and imported cases confirmed COVID-19 in Yunnan Hospital of 108 
Infectious Diseases from January to May 2020. The strain with mutation of D614G in S 109 
protein was isolated from a child patient who returned from U.S. to hometown and was 110 
identified being infected by SARS-CoV-2 through clinical diagnostic and q-RT-PCR in March, 111 
2020. The virus was proliferated in Vero cells (WHO) and was titrated with a microtitration 112 
assay. Vero cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Corning, NY, 113 
USA) containing 5% fetal bovine serum (FCS; HyClone, Logan, USA). 114 
 115 
Inactivated vaccine 116 
The SARS-CoV-2 inactivated vaccine was developed by the Institute of Medical Biology (IMB), 117 
Chinese Academy of Medical Sciences (CAMS). Briefly, the virus strain, named KMS-1 118 
(GenBank No: MT226610.1), was inoculated into Vero cells for production in an environment 119 
that met the BSL requirements. The harvested viruses were inactivated by formaldehyde 120 
(v:v=1:4000) for 48 h to lyse the viral membrane, purified via chromatography and 121 
concentrated. A second inactivation with beta-propiolactone (v:v=1:2000) was performed to 122 
destroy the viral genomic structure, followed by a second purification and concentration 123 
using the same protocol. The vaccine stock was evaluated using various quality indexes, 124 
including antigen content, immunogenicity, sterility and residue testing. The viral antigen 125 
content was measured via ELISA. The vaccine contained 50, 100 or 150 EU of inactivated viral 126 
antigen adsorbed to 0.25 mg of Al(OH)3 adjuvant and suspended in 0.5 ml of buffered saline 127 
for each dose. The placebo contained only the same amount of Al(OH)3 in buffer. 128 
 129 
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Study design and participants 130 
The trial was designed based upon the principles of randomization, double-blinding and 131 
placebo control. The study protocol was reviewed and approved by the Ethics Committee of 132 
the West China Second University Hospital, Sichuan University. An independent data safety 133 
monitoring board was established to oversee the safety data during the study, specifically 134 
during the 7 days after each inoculation (p.i.). The trial was conducted according to the 135 
principles of the Declaration of Helsinki and Good Clinical Practice at the West China Second 136 
University Hospital, Sichuan University. Healthy volunteers 18 to 59 years of age were eligible 137 
for enrollment after providing informed consent. The inclusion and exclusion criteria are 138 
listed in the supplementary appendix. The enrolled participants were randomly assigned at a 139 
ratio of 1:1 to receive two inoculations at an interval of 14 days or 28 days, and the subjects 140 
in each schedule were assigned at a ratio of 1:1:1:1 to receive one of the three vaccine doses 141 
(50 EU, 100 EU and 150 EU) or the placebo. All the enrolled participants were asked to record 142 
solicited and unsolicited adverse events, if any, for a period of 28 days. Study staff visited 143 
participants on site to track their health status and determine whether they needed medical 144 
care. Blood samples were taken from the enrolled participants at days 0 (baseline), 7, 14 and 145 
28 (0, 14 schedule) or 7 and 28 (0, 28 schedule) days postimmunization to evaluate the 146 
immunogenicity of the vaccine at different time points and to determine the vaccine safety 147 
profile through the detection of 48 cytokines in the serum, the assessment of possible ADEs 148 
with regard to viral infection and the analysis of mRNA gene expression in peripheral blood 149 
mononuclear cells (PBMCs). 150 
 151 
End points of the clinical trial 152 
The primary end point was the total rate of adverse reactions from 0 to 28 days 153 
postimmunization. The secondary end points were serological evidence of the 154 
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immunogenicity of the vaccine. 155 
 156 
Statistical analysis 157 
Descriptive statistics (means and standard deviations for normally distributed variables, 158 
medians and IQRs for nonnormally distributed variable) were used for continuous variables, 159 
while frequencies and proportions were used for categorical variables. The safety analysis 160 
was performed with the data from the participants who had received at least one dose of 161 
the vaccine and for whom safety data were available. The numbers and proportions of 162 
participants with adverse reactions or events were summarized. The immunogenicity 163 
analysis was conducted with the data from the full cohort, including all participants who 164 
received injections and had results for the antibody test. The antibodies against SARS-CoV-2 165 
are summarized as geometric mean titers with 95% CIs, and the cellular responses are 166 
presented as the proportion of positive responders. The chi-square test or Fisher’s exact test 167 
was used to analyze the categorical data, and the t-test or Wilcoxon rank-sum test (for 168 
nonnormally distributed data) was used to compare log-transformed antibody titers. A P 169 
value lower than 0.05 (two-sided) was considered to be significant. The statistical analysis 170 
was performed by an independent statistician using GraphPad Prism software (San Diego, CA, 171 
USA) and STATA software (Version 15.0; STATA Corp., College Station, TX, USA). 172 
 173 
Laboratory detection 174 
Neutralizing antibody test 175 
The neutralizing antibody assay was performed via microtitration, and the neutralizing titer 176 
in the sera was determined by CPE observation. A brief description is attached in the 177 
supplemental appendix. 178 
ELISA 179 
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ELISAs were conducted with antibodies against the S protein, N protein and virions that were 180 
developed by this institute. A brief description can be found in the supplemental appendix. 181 
ELISpot 182 
An ELISpot assay was performed with a Human IFN-γ ELISpot Kit (Mabtech, Cincinnati, OH, 183 
USA) according to the manufacturer’s protocol. A brief description is attached in the 184 
supplemental appendix. 185 
Immune cell populations 186 
The isolation of immune cell populations was performed according to a standard protocol. A 187 
brief description can be found in the supplemental appendix. 188 
Cytokine assay 189 
Detection of 48 cytokines in human peripheral blood was performed according to the kit 190 
manufacturer’s instructions. A brief description is attached in the supplemental appendix. 191 
Transcriptome assay 192 
Transcriptome assays were performed by Novogene Co., Ltd., China. To exclude individual 193 
differences, each group included two samples (A and B) at each time point, and each sample 194 
was mixed with PBMCs from five individuals. The raw microarray data were submitted to the 195 
National Genomics Data Center (NGDC) and are available (PRJCA003531). A brief description 196 
is attached in the supplemental appendix. 197 
 198 
ADE detection 199 
Human NK cells, DCs, and mononuclear/macrophages isolated from donors who provided 200 
their informed consent were infected by the virus in different multiplicities of infection (MOIs) 201 
in the presence of mixed sera from 12 immunized individuals that had the same neutralizing 202 
titer and were diluted from 1:32 to 1:4096. Antibody-dependent enhancement (ADE) was 203 
determined via viral load detection by q-RT-PCR at various time points. A brief description is 204 
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attached in the supplemental appendix. 205 
qRT-PCR 206 
The RNA extraction and qRT-PCR assay was according standard protocol. The brief 207 
description can be seen in supplemental appendix. 208 
 209 
Results 210 
Study participants 211 
   A total of 294 adults aged 18 to 59 years were evaluated for inclusion in this phase I trial. 212 
Among them, 102 persons were excluded, of whom 84 were ineligible, and 18 withdrew 213 
their informed consent. The remaining 192 participants were randomly assigned at a ratio of 214 
1:1 to receive two inoculations with an intervening interval of 14 days or 28 days, and 215 
subjects for each schedule were assigned at a ratio of 1:1:1:1 to receive one of the three 216 
doses of the vaccine or the placebo (Fig. 1). 217 
   From May 2020 through August 2020, all participants who received two inoculations of 218 
the vaccine or placebo were monitored for any clinical manifestations and were required to 219 
provide blood samples 3 (0, 14 schedule) or 2 (0, 28 schedule) times after inoculation. The 220 
withdrawal rate was 0.5%: 1 participant in the low-dose group who was assigned to the 0, 28 221 
schedule did not receive the second dose. The 191 participants were divided as follows: 24 in 222 
each of the three different dose groups and the control group assigned to the 0, 14 schedule 223 
and 23, 24, 24 and 24 in the low-dose, medium-dose, high-dose and control groups assigned 224 
to the 0, 28 schedule (Fig. 1). The demographic characteristics of the participants in each 225 
group are shown in Table 1. 226 
 227 
Comprehensive observation of adverse reactions 228 
   Because knowledge of the pathogenesis of SARS-CoV-2 infection is still lacking 
11,12
, in this 229 
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trial, the specific vaccine safety concern was abnormal immunopathologic events. We 230 
observed not only solicited clinical adverse reactions for 7 days after each inoculation and 231 
unsolicited events for 28 days after the full vaccination but also the variations in cytokine 232 
levels in the serum of 50% of the subjects inoculated with the vaccine or placebo. 233 
Furthermore, based on the serious concern regarding a possible ADE effect in vaccine 234 
development 
13
, the immune serum samples from vaccinated individuals were investigated 235 
across a range of dilutions for possible ADE. The 18 solicited systemic adverse reactions 236 
observed in the 7 days after each inoculation were distributed as follows: 3, 1, 1 and 0 in the 237 
low-dose, medium-dose, high-dose and placebo groups assigned to the 0 and 14 schedule 238 
and 2, 4, 4, and 3 in those groups assigned to the 0 28 schedule. Unsolicited reactions were 239 
reported by 8.3%, 0.0%, and 8.3% of the participants in the low-, medium- and high-dose 240 
groups compared to 0.0% in the placebo group among those assigned to the 0, 14 schedule, 241 
while they were reported by 0.0%, 8.3%, and 12.5% of the participants in the low-, medium- 242 
and high-dose groups compared to 4.2% in the placebo group among those assigned to the 0, 243 
28 schedule. The most common adverse reactions were mild pain and redness at the 244 
injection site and slight fatigue. No severe (grade 3) adverse reactions or serious reactions 245 
were observed within 28 days (Table 2). Furthermore, the levels of various cytokines in the 246 
sera of immunized subjects in the 3 dose groups following the 2 schedules did not show 247 
abnormalities compared to those in the sera from subjects in the placebo groups (Fig. 2). 248 
There were no significant differences between the vaccine and placebo groups with regard to 249 
the counts of various T cell populations in the peripheral blood (Supplemental Fig. 1). To 250 
investigate possible ADE in individuals immunized with the inactivated vaccine, immune sera 251 
collected from 15 subjects with similar neutralizing antibody titers were mixed and diluted 252 
from 1:32 to 1:4096 and then incubated with SARS-CoV-2 for inoculating the cultured human 253 
DCs, NK cells and mononuclear cells/macrophages followed by the detection of dynamic viral 254 
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proliferation in the cells and supernatant. The results did not show variations of dynamic 255 
viral proliferation with existence of immune sera rather than 1-2 fold compared to viral 256 
control, and suggest that the immunized sera in the dilution range of 1:32 to 1:4096 do not 257 
lead to ADE in these human immune cells compared with sera from individuals in the 258 
placebo group and the positive Dengue virus control group (Fig. 3). These results suggest that 259 
there are no immunopathologic events related to vaccination. 260 
 261 
Assessment of immunity elicited in the 3 dose groups assigned to the 2 schedules 262 
  The results obtained for the three dose groups assigned to the two schedules with regard 263 
to the neutralizing antibody titers of the immunized subjects in the groups assigned to the 0, 264 
14 schedule showed seroconversion rates of 55%, 100% and 88% in the low-, medium- and 265 
high-dose groups compared to the placebo group at day 7 after the booster, and their 266 
geometric mean titers (GMTs) increased by 5.0, 42.5 and 24.4, respectively. Furthermore, at 267 
day 14, the seroconversion rates in the three groups reached 92%, 100% and 96%, with GMTs 268 
of 18.0, 54.5 and 37.1, respectively (Fig. 4a). However, there appeared to be a decreasing 269 
trend in the neutralizing antibody titers from day 14 to day 28 (Fig. 4a). In the groups 270 
assigned to the 0, 28 schedule, the seroconversion rate of the neutralizing antibodies 271 
reached 80%, 96% and 92%, with GMTs of 10.6, 15.4 and 19.6, at day 28 after immunization, 272 
with an increasing trend starting from day 7 after immunization (Fig. 4b). Significantly, ELISA 273 
with antibodies against the S protein, N protein and virion showed essentially synchronous 274 
increases regardless of the schedule to which the participants were assigned (Fig. 4a, b). The 275 
specific positive CTL responses against the S protein, N protein and virion in the ELISpot assay 276 
indicated a distinct increase at day 28 after the booster for both schedules (Fig. 4a, b). These 277 
results suggest that the vaccine elicits a synchronous dynamic response involving antibodies 278 
and CTLs against the viral antigens. The subsequent serological detection in the available 279 
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serum samples of 23 subjects immunized with the medium dose of the vaccine at 90 days 280 
after the second inoculation suggested that the seroconversion rate of the neutralizing 281 
antibodies was 91.3% with a GMT of 8.5, while the ELISA antibodies showed 100% of 282 
seroversion including anti-S, anti-N and anti-virion antibodies of 91%, 61% and 83% with 283 
GMTs of 656, 594 and 691, respectively (Fig. 4c). The IgG1 subtype was the common subtype 284 
against all three antigens (Table S1). Additionally, the immune sera were found to neutralize 285 
the pandemic strains in North America (Fig. 4d) with the D614G mutation in the S protein 286 
(Supplemental Fig. 2) 
14
. To characterize the immunogenicity of the vaccine, we performed a 287 
comparative analysis of the mRNA profile of PBMCs from immunized individuals of 288 
medium-dose group in two schedules at day 7 and 28 after full immunization to shape the 289 
genetic diversity of the immune response elicited by the vaccine. The results suggest that the 290 
vaccine initiates and promotes a series of transcriptional activities in immune cells, which 291 
lead to the significant upregulation of many genes related to the immune response. The 292 
classification of all the different upregulated genes into various immune functions suggests 293 
that the immunization by the vaccine of medium-dose in two schedules results in the specific 294 
activation of the innate and adaptive immune responses compared to the placebo control. 295 
However, the expression of certain significant cytokine genes, including IL-6, IL-1, IL-2, TNF-α 296 
and IFN-γ, which were found to be distinctly increased in the peripheral blood of COVID-19 297 
patients, varied only slightly compared to those in the placebo controls (Fig. 5a). 298 
Furthermore, our data indicate that the genes related to T and B cell activation were 299 
upregulated by approximately 40% and 25%, respectively, at day 7 after the second 300 
inoculation and varied dynamically during the periods from day 7 to day 14 or from day 7 to 301 
day 28 in two schedules (Fig. 5b, c). The genes related to the activation of DCs, mononuclear 302 
cells/macrophages and NK cells were upregulated to varying degrees in the same periods (Fig. 303 
5d, e, f). All these results describe a specific genetic background of the immune response 304 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted October 6, 2020. .https://doi.org/10.1101/2020.09.27.20189548doi: medRxiv preprint 
14 
 
elicited by the vaccine. 305 
 306 
Discussion 307 
  Given the urgent need to control the COVID-19 pandemic, vaccine development is being 308 
accelerated into the clinical trials phase 
4,7,8
, even though understanding of the immunologic 309 
features of the antigens of SARS-CoV-2 remains poor. In this phase I trial, a study was 310 
performed to investigate the safety and immunogenicity of this inactivated vaccine in 191 311 
subjects. The data collected show several notable features. First, the clinical safety 312 
observations among the 191 subjects suggest that there were no severe adverse reactions 313 
related to vaccination, and the most frequently reported events were mild, including redness, 314 
itching and swelling at the inoculation site and a few cases of slight fatigue; there were no 315 
significant differences between the vaccine and control groups. These data support the 316 
clinical safety of this vaccine. However, based on the current concern about the possibility of 317 
immunopathology due to SARS-Cov-2 infection 
13
, we extended our safety observation to the 318 
investigation of variations in cytokine levels in the serum, with particular attention paid to 319 
the possibility of ADE related to antibodies induced by vaccination 
12,15
. The test results 320 
suggested that there were no abnormalities in most of the 48 detected cytokines. In the 321 
dilution range of 1:32 to 1:4096, no ADE was observed in the virus-infected DCs, NK cells or 322 
mononuclear cells/macrophages in the immune sera from vaccinated individuals. Although 323 
we cannot conclude that this vaccine will not cause ADE, these observations at least suggest 324 
that the likelihood of ADE as a result of inoculation with this vaccine is small. Second, 325 
serological detection showed not only neutralizing antibody but also ELISA antibodies against 326 
the S protein, N protein and complete virion antigens elicited in the vaccinated population, 327 
and there were dynamic alterations based on the dose and vaccination schedule. However, 328 
the medium and high doses in both the 0, 14 and 0, 28 schedule groups led to 100% 329 
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seroconversion of ELISA anti-S antibody after two inoculations, and interestingly, the medium 330 
dose group assigned to the 0, 14 schedule reached 100% seroconversion of the neutralizing 331 
antibody with the highest GMT value. Importantly, the neutralizing antibody can neutralize 332 
different pandemic strains with diverse mutations. At the time of the antibody response, a 333 
CTL response with IFN-r specificity against the S, N and virion antigens was detected in 334 
immunized individuals in comparison with individuals receiving placebo, which suggests that 335 
any one of three antigens enables the specific activation of T cells, even if they do not show 336 
dose-dependent effects. These immunological indexes indicate a systemic immune response 337 
elicited by our vaccine in the human population. To shape the genetic diversity of the specific 338 
immunity elicited by the vaccine, we examined the mRNA gene profile of the PBMCs from 339 
vaccinated individuals and found that most of the expressed mRNA genes were related to 340 
various signaling pathways of the innate and adaptive immune systems, and the immune 341 
functions were upregulated in comparison with the placebo group. Here, activation of the 342 
multiple signaling pathways involved in the immune response resulted in variations in 343 
hundreds of genes related to activation of innate immunity at day 7 after immunization 344 
regardless of the immunization schedule; however, the cytokines that were found to have 345 
elevated levels in COVID-19 patients had only mild variations and were at levels similar to 346 
those in the placebo control group, which corresponded with those detected in the serum. 347 
The activation of genes related to T cells, B cells, DCs and mononuclear cells/macrophages 348 
with varying dynamics is evidence of the immune response elicited by the vaccine. All the 349 
data obtained in this trial support the safety and immunogenicity of this inactivated vaccine 350 
and are encouraging with regard to further studies of its efficacy in the future. 351 
A limitation of this study is the lack of protective efficacy analysis and data from a parallel 352 
contrasting analysis of the transcriptome of PBMCs from individuals immunized with the 353 
vaccine and of those from COVID-19 patients, which was due to a lack of samples. 354 
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Figure legends 410 
Fig. 1 Screening, randomization and inclusion in phase I clinical trial 411 
 412 
Fig. 2 Variations in 48 cytokines in the serum of immunized individuals and the observation 413 
of ADE. 414 
Levels of 48 cytokines were monitored in the serum of the subjects who received the vaccine 415 
and placebo who were assigned to the 0, 14 schedule (black) or the 0, 28 schedule (blue). 416 
Cytokines were Chemokines, interleukins (ILs), growth factors (GFs), colony stimulating 417 
factors (CSFs), tumor necrosis factors (TNFs), interferon (IFNs). The levels of 48 cytokines 418 
(pg/mL) in the serum of subjects before receiving vaccine and placebo are shown as gray 419 
intervals between red spots in each figure. Control (Con, 0 EU), low dose (LD, 50 EU), middle 420 
dose (MD, 100 EU) and high dose (HD, 150 EU). 421 
 422 
Fig. 3 The observation of ADE. 423 
a-c: Fold change in relative viral load of supernatant and cell lysate of mononuclear 424 
cells/macrophages (a), DCs (b) and NK cells (c) from human PBMCs infected with SARS-CoV-2 425 
at three MOI in the presence of a series of dilutions of vaccine immune serum (1:32, 1:64, 426 
1:128, ... to 1:4096) quantified by real-time PCR. Viral load of cell lysate were normalized to 427 
viral copies in cell lysate of Virus group at 12 hours, and viral load of supernatant were 428 
normalized to viral copies in virus input at 0 hour. Vac-sera, vaccine immune antisera from 429 
human; cov-sera, convalescent antisera from COVID-19 patients; ctrl-sera, control sera from 430 
healthy human. Data are shown as the mean ± SEM.  431 
d: Fold change in relative viral load of supernatant and cell lysate of mononuclear 432 
cells/macrophages, DCs and NK cells from human PBMCs infected with DENV-3 in the 433 
presence of mAb against prM quantified by real-time PCR. Viral load of cell lysate were 434 
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normalized to viral copies in cell lysate of Virus group at 12 hours, and viral load of 435 
supernatant were normalized to viral copies in virus input at 0 hour. Data are shown as the 436 
mean ± SEM. 437 
 438 
Fig. 4 Immune response induced in immunized human individuals with inactivated 439 
SARS-Cov-2 vaccine in the 0, 14 and 0, 28 schedules. 440 
a. Neutralizing antibodies, ELISA antibodies (IgGs) against S protein, N protein and virion, 441 
and the specific positive CTL responses against the S, N and virion antigens induced by 442 
the inactivated vaccine in individuals assigned to the 0, 14 schedule after booster 443 
immunization.  444 
b. Neutralizing antibodies, ELISA antibodies (IgGs) against S protein, N protein and virion, 445 
and the specific positive CTL responses against the S, N and virion antigens induced by 446 
the inactivated vaccine in individuals assigned to the 0, 28 schedule after booster 447 
immunization. 448 
c. Neutralizing antibodies, ELISA antibodies (IgGs) against S protein, N protein and virion 449 
induced by the inactivated vaccine in individuals assigned to the 0, 28 schedule on 90 450 
days after booster immunization. 451 
d. Neutralizing antibodies induced by the inactivated vaccine could identify pandemic 452 
strains from all over the world. 453 
Control (Con, 0 EU), low dose (LD, 50 EU), middle dose (MD, 100 EU) and high dose (HD, 150 454 
EU). The antibody positive judgment threshold is marked with a dotted line in the figure. *, 455 
0.01<p<0.05; **, 0.001<p<0.01; ***, p<0.001. The significant differences compared to the 456 
control group (Con) are shown in black, those compared to the low-dose group in purple, 457 
and those compared to the middle-dose group in red. 458 
 459 
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Fig. 5 Genetic diversity of genes related to the immune response induced by the 460 
inactivated SARS-Cov-2 vaccine. 461 
a. The fold changes in some of the differentially expressed genes involved in cytokine 462 
production. Some important genes reported relating to COVID-19 were marked with the 463 
pink rectangle. 464 
b. The fold changes in some of the differentially expressed genes involved in T cell 465 
activation. 466 
c. The fold changes in some of the differentially expressed genes involved in B cell 467 
activation. 468 
d. The fold changes in some of the differentially expressed genes involved in DC cell 469 
activation. 470 
e. The fold changes in some of the differentially expressed genes involved in mononuclear 471 
cell/macrophage activation. 472 
f. The fold changes in some of the differentially expressed genes involved in NK cell 473 
activation. 474 
Each row represents one gene, and the samples are depicted in the columns. Red indicates 475 
genes that were expressed at higher levels, and blue denotes genes that were expressed at 476 
lower levels compared with the control group at the same time point. The color bars 477 
represent the log2 fold change. 478 
 479 
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Table 1. Baseline characteristics of the study participants 
Characteristic 
Immunization Schedule: Day 0,14 (N=96) 
 
Immunization Schedule: Day 0,28 (N=96) 
Low dose  
group (n=24) 
Medium dose  
group (n=24) 







Low dose  
group (n=24) 
Medium dose  
group (n=24) 






Age     
  
    
 
18-29 9 (38%) 7 (29%) 11 (46%) 5 (21%) 32 (33%) 
 
8 (33%) 4 (17%) 7 (29%) 5 (21%) 24 (25%) 
30-39 4 (17%) 6 (25%) 7 (29%) 10 (42%) 27 (28%) 
 
9 (38%) 7 (29%) 9 (38%) 10 (42%) 35 (36%) 
40-49 7 (29%) 7 (29%) 3 (13%) 6 (25%) 23 (24%) 
 
7 (29%) 11 (46%) 3 (13%) 7 (29%) 28 (29%) 
50-59 4 (17%) 4 (17%) 3 (13%) 3 (13%) 14 (15%) 
 
0 2 (8%) 5 (21%) 2 (8%) 9 (9%) 
Mean(SD) 37.0±11.84 38.2±10.83 33.9±11.00 37.6±9.04 36.7±10.69 
 
34.4±9.21 40.1±9.70 36.5±11.43 37.2±8.67 37.0±9.86 
Sex     
  
     
Male 11 (46%) 8 (33%) 10 (42%) 14 (58%) 43 (45%) 
 
9 (38%) 12 (50%) 10 (42%) 12 (50%) 43 (45%) 
Female 13 (54%) 16 (67%) 14 (58%) 10 (42%) 53 (55%) 
 
15 (63%) 12 (50%) 14 (58%) 12 (50%) 53 (55%) 
BMI,  kg/m2     
  
     
Mean(SD) 23.6±2.80 23.0±2.76 23.0±2.96 23.0±2.70 23.1±2.77 
 
22.7±2.83 22.8±2.73 22.6±1.37 23.3±2.39 22.9±2.38 
Ethnicity     
  
     
Han 24 (100%) 22 (92%) 22 (92%) 24 (100%) 92 (96%) 
 
22 (92%) 24 (100%) 24 (100%) 24 (100%) 94 (98%) 
Man 0 0 0 0 0 
 
1 (4%) 0 0 0 1 (1%) 
Hmong 0 1 (4%) 0 0 1 (1%) 
 
0 0 0 0 0 
Tujia 0 0 1 (4%) 0 1 (1%) 
 
0 0 0 0 0 
Tibetan 0 1 (4%) 1 (4%) 0 2 (2%) 
 
1 (4%) 0 0 0 1 (1%) 
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Table 2. Adverse events within 28 days after vaccination in the safety population. 
 
Adverse reactions 

















 number of participants (%)  number of participants (%) 
All adverse reactions within 0-7 days  8 (33.3) 4 (16.7) 4 (16.7) 3 (12.5)  5 (20.8) 7 (29.2) 9 (37.5) 4 (16.7) 
Solicited injection site adverse reactions within 0-7 days 
Total 7 (29.2) 4 (16.7) 2 (8.3) 3 (12.5)  3 (12.5) 4 (16.7) 5 (20.8) 0 (0.0) 
Pain 6 (25.0) 4 (16.7) 2 (8.3) 2 (8.3)  3 (12.5) 3 (12.5) 5 (20.8) 0 (0.0) 
Itch 2 (8.3) 1 (4.2) 0 (0.0) 1 (4.2)  0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Redness 1 (4.2) 0 (0.0) 0 (0.0) 1 (4.2)  0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Swelling 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)  0 (0.0) 1 (4.2) 0 (0.0) 0 (0.0) 
Solicited systemic adverse reactions within 0-7 days 
Total 3 (12.5) 1 (4.2) 1 (4.2) 0 (0.0)  2 (8.3) 4 (16.7) 4 (16.7) 3 (12.5) 
Fatigue 2 (8.3) 1 (4.2) 0 (0.0) 0 (0.0)  2 (8.3) 3 (12.5) 3 (12.5) 2 (8.3) 
Diarrhoea 0 (0.0) 1 (4.2) 1 (4.2) 0 (0.0)  0 (0.0) 0 (0.0) 1 (4.2) 0 (0.0) 
Fever 1 (4.2) 0 (0.0) 0 (0.0) 0 (0.0)  0 (0.0) 1 (4.2) 0 (0.0) 0 (0.0) 
Rash 1 (4.2) 0 (0.0) 0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0) 0 (0.0) 1 (4.2) 
Unsolicited adverse reactions within 0-7 days 2 (8.3) 0 (0.0) 2 (8.3) 0 (0.0)  0 (0.0) 2 (8.3) 3 (12.5) 1 (4.2) 
Overall adverse reactions within 0-28 days 8 (33.3) 4 (16.7) 4 (16.7) 3 (12.5)  6 (25.0) 7 (29.2) 9 (37.5) 3 (12.5) 
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